1. Home
  2. OPY vs NBTX Comparison

OPY vs NBTX Comparison

Compare OPY & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oppenheimer Holdings Inc. (DE)

OPY

Oppenheimer Holdings Inc. (DE)

HOLD

Current Price

$86.00

Market Cap

956.2M

Sector

Finance

ML Signal

HOLD

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

HOLD

Current Price

$31.30

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPY
NBTX
Founded
1881
2003
Country
United States
France
Employees
2973
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
956.2M
1.0B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
OPY
NBTX
Price
$86.00
$31.30
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$26.00
AVG Volume (30 Days)
49.8K
20.7K
Earning Date
05-01-2026
01-01-0001
Dividend Yield
0.80%
N/A
EPS Growth
104.71
N/A
EPS
13.04
N/A
Revenue
$1,638,071,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.73
P/E Ratio
$13.82
N/A
Revenue Growth
14.35
N/A
52 Week Low
$49.26
$2.95
52 Week High
$94.10
$30.23

Technical Indicators

Market Signals
Indicator
OPY
NBTX
Relative Strength Index (RSI) 51.84 73.91
Support Level $84.00 $20.11
Resistance Level $94.10 N/A
Average True Range (ATR) 3.04 1.61
MACD -0.52 0.46
Stochastic Oscillator 19.81 97.92

Price Performance

Historical Comparison
OPY
NBTX

About OPY Oppenheimer Holdings Inc. (DE)

Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Share on Social Networks: